Physicians anticipate new oral therapies for multiple sclerosis patients

Links shared publicly online about this topic.

805
total visits

Physicians anticipate new oral therapies for multiple sclerosis patients

Physicians are anticipating the arrival of new oral therapies for multiple sclerosis patients, with initial research showing very high awareness of oral candidates, particularly Novartis' Gilenya, which received FDA approval for relapsing forms of the disease in late September. The majority of neurologists expect Gilenya to be very useful as a therapy and trial of the drug is predicted to be strong, according to new research by GfK HealthCare.

View full resource at news-medical.net

Tags: Multiple Sclerosis, Disease and Condition, FDA, Physician, Neurologist, disease